DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology; German Cancer Research Center ; Heidelberg, Germany ; Department of Neurooncology; University Hospital Heidelberg ; Heidelberg, Germany.
DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology; German Cancer Research Center ; Heidelberg, Germany ; DKTK Clinical Cooperation Unit Neurooncology; German Cancer Research Center ; Heidelberg, Germany.
Oncoimmunology. 2015 Jan 7;3(12):e974392. doi: 10.4161/2162402X.2014.974392. eCollection 2014 Dec.
The discovery of driver mutations in cancers has raised interest in their suitability as immunotherapeutic targets. A recent study demonstrates that a point mutation in isocitrate dehydrogenase 1 (IDH1R132H), expressed in gliomas and other tumors, is presented on human MHC class II and induces a mutation-specific CD4 antitumor T cell response in patients and a syngeneic tumor model in MHC-humanized mice.
在癌症中发现驱动突变后，人们对其作为免疫治疗靶点的适用性产生了兴趣。最近的一项研究表明，在胶质瘤和其他肿瘤中表达的异柠檬酸脱氢酶 1（IDH1R132H）中的点突变可呈递在人 MHC Ⅱ类分子上，并在患者和 MHC 人源化小鼠的同种异体肿瘤模型中诱导突变特异性 CD4 抗肿瘤 T 细胞应答。
